Urothelial Cancer
2021 Year in Review - Triple-Negative Breast Cancer | February 18, 2022
Responses to first- and second-line chemotherapy regimens for metastatic urothelial carcinoma (mUC) have been less than satisfactory, creating an unmet need for new treatment options for this disease.
December 2019 Vol 10, No 12 | December 2, 2019
Patients with metastatic urothelial cancer receive first-line treatment with platinum-based chemotherapy and second-line treatment with a checkpoint inhibitor.
May 2019 Vol 10, No 5 | May 7, 2019
Sacituzumab govitecan, a novel antibody-drug conjugate directed against Trop-2, induced response in nearly 33% of patients with heavily pretreated, relapsed, or refractory metastatic urothelial cancer.
March 2016 Vol 7, No 2 | March 4, 2016
The incidence of diabetes and urologic diseases is
widespread, and increases with age.
Results 1 - 5 of 5
